ProKidney (PROK) Competitors $3.17 +0.08 (+2.59%) Closing price 04:00 PM EasternExtended Trading$3.18 +0.01 (+0.32%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. ZLAB, AAPG, SRRK, AKRO, NAMS, MIRM, LNTH, VKTX, ACAD, and ADMAShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Zai Lab (ZLAB), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Akero Therapeutics (AKRO), NewAmsterdam Pharma (NAMS), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Its Competitors Zai Lab Ascentage Pharma Group International Scholar Rock Akero Therapeutics NewAmsterdam Pharma Mirum Pharmaceuticals Lantheus Viking Therapeutics ACADIA Pharmaceuticals ADMA Biologics Zai Lab (NASDAQ:ZLAB) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in ZLAB or PROK? 41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 5.0% of Zai Lab shares are owned by insiders. Comparatively, 41.5% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate ZLAB or PROK? Zai Lab presently has a consensus target price of $56.35, suggesting a potential upside of 91.73%. ProKidney has a consensus target price of $6.25, suggesting a potential upside of 97.16%. Given ProKidney's higher possible upside, analysts plainly believe ProKidney is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zai Lab 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63ProKidney 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has stronger earnings & valuation, ZLAB or PROK? ProKidney has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZai Lab$398.99M8.23-$257.10M-$2.04-14.41ProKidney$80K11,660.85-$61.19M-$0.57-5.56 Is ZLAB or PROK more profitable? ProKidney has a net margin of 0.00% compared to Zai Lab's net margin of -49.68%. ProKidney's return on equity of 0.00% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zai Lab-49.68% -27.32% -18.85% ProKidney N/A N/A -17.11% Which has more volatility and risk, ZLAB or PROK? Zai Lab has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.72, indicating that its share price is 72% more volatile than the S&P 500. Does the media favor ZLAB or PROK? In the previous week, Zai Lab had 4 more articles in the media than ProKidney. MarketBeat recorded 8 mentions for Zai Lab and 4 mentions for ProKidney. ProKidney's average media sentiment score of 0.88 beat Zai Lab's score of 0.34 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ProKidney 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryProKidney beats Zai Lab on 12 of the 16 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$909.33M$2.96B$6.11B$10.47BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-5.5622.7985.3627.36Price / Sales11,660.85763.51607.44135.43Price / CashN/A172.6337.4661.86Price / Book-0.935.5112.426.81Net Income-$61.19M$33.06M$3.32B$276.80M7 Day Performance-2.76%0.95%1.01%0.27%1 Month Performance29.39%14.25%10.75%8.31%1 Year Performance83.24%0.85%76.20%35.60% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney2.6427 of 5 stars$3.17+2.6%$6.25+97.2%+76.6%$909.33M$80K-5.563ZLABZai Lab2.7796 of 5 stars$33.69+2.4%$56.35+67.3%+18.9%$3.77B$398.99M-16.511,869News CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$40.23+3.5%N/AN/A$3.75B$134.35M0.00600News CoverageSRRKScholar Rock4.6723 of 5 stars$38.69-2.1%$46.40+19.9%+11.9%$3.72B$33.19M-13.30140Options VolumeHigh Trading VolumeAKROAkero Therapeutics3.6818 of 5 stars$46.49+1.1%$81.14+74.5%+79.3%$3.72BN/A-23.2530Insider TradeNAMSNewAmsterdam Pharma1.5633 of 5 stars$32.86+2.0%$42.00+27.8%+97.6%$3.70B$45.56M-20.284MIRMMirum Pharmaceuticals2.8814 of 5 stars$72.85-1.2%$76.50+5.0%+84.3%$3.66B$336.89M-60.21140Positive NewsHigh Trading VolumeLNTHLantheus4.562 of 5 stars$53.55+3.3%$74.50+39.1%-50.3%$3.64B$1.53B14.24700Trending NewsAnalyst RevisionHigh Trading VolumeVKTXViking Therapeutics3.9698 of 5 stars$32.37+2.7%$86.42+167.0%-49.8%$3.64BN/A-21.1620Upcoming EarningsACADACADIA Pharmaceuticals4.5141 of 5 stars$21.31-1.1%$29.12+36.6%+35.8%$3.60B$957.80M16.02510Analyst ForecastADMAADMA Biologics3.5043 of 5 stars$14.62+4.5%$27.67+89.2%-8.7%$3.49B$426.45M17.00530News Coverage Related Companies and Tools Related Companies ZLAB Alternatives AAPG Alternatives SRRK Alternatives AKRO Alternatives NAMS Alternatives MIRM Alternatives LNTH Alternatives VKTX Alternatives ACAD Alternatives ADMA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
